the aadi bioscience ( aADI ) program is a multidisciplinary team team that is able to provide therapies that improve the lives of patients with malignant uterine pecoma. we have been able to deliver the first product for the treatment of malignant pecoma in the year and we have received a permanent j code for fiscalaro. we achieved sales of $15.2 million in 2022 outperforming estimates for the year in just 10 months on the market. we have been excited about the potential benefits of fiscalaro for patients beyond pecoma. we are excited about the potential for FYaro to provide benefits for patients beyond pecoma. we will now turn it back to our chief medical officer, Lorettaitri, and our clinical developments and plans for 2023.